Nurix Therapeutics Inc
NRIXHealthcare|Biotechnology|USA
$23.08
-1.63 (-6.60%)
Tangible Book
$3.88
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07221500 A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | P2 | Recruiting | 100 | Open-label | NX-5948 |
| NCT04830137 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | P1 | Recruiting | 248 | Open-label | NX-2127 |
| NCT06717269 Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets | Healthy Volunteer | P1 | Recruiting | 18 | Open-label | NX-5948, Esomeprazole |
| NCT05107674 A Study of NX-1607 in Adults With Advanced Malignancies | Ovarian Cancer, Epithelial, Gastric Cancer | P1 | Recruiting | 345 | Open-label | NX-1607, Paclitaxel |
| NCT05131022 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | P1 | Recruiting | 572 | Open-label | NX-5948 |
| NCT07516093 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | B-cell Lymphoma, Chronic Lymphocytic Leukemia | P3 | Not Yet Recruiting | 620 | RCT, Open-label | NX-5948, Pirtobrutinib |
| NCT07520006 Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | B-cell Lymphoma, Chronic Lymphocytic Leukemia | P1P2 | Not Yet Recruiting | 150 | Open-label | NX-5948, venetoclax, rituximab, obinutuzumab |
| NCT06593457 A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | IP, Matching Placebo |
| NCT05107739 A Study of DeTIL-0255 in Adults With Advanced Malignancies | Platinum-resistant Ovarian Cancer, Endometrial Cancer | P1 | Terminated | 5 | Open-label | Drug Product De-TIL-0255 |
| NCT06691828 Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948 | Healthy Volunteer | P1 | Completed | 8 | Open-label | NX-5948 |